Pitarokoili, Kalliopi
Gold, Ralf
Article History
First Online: 29 July 2019
Competing interests
: K.P. has received speaker honoraria and travel funding from Bayer Schering Pharma, Biogen Idec, Celgene, CSL Behring, Grifols and Novartis. R.G. serves on scientific advisory boards for Bayer Schering Pharma, Biogen Idec, Novartis and Teva Pharmaceutical Industries; has received speaker honoraria from Bayer Schering Pharma, Biogen Idec, Novartis and Teva Pharmaceutical Industries; serves as editor for <i>Therapeutic Advances in Neurological Diseases</i> and is on the editorial boards of <i>Experimental Neurology</i> and the <i>Journal of Neuroimmunology</i>; and receives research support from Bayer Schering Pharma, Biogen Idec, Genzyme, Merck Serono, Novartis and Teva Pharmaceutical Industries, none of which are related to this manuscript.